{"id":363,"date":"2013-07-12T15:06:09","date_gmt":"2013-07-12T06:06:09","guid":{"rendered":"http:\/\/www.keyton-co.jp\/kpharm\/byotai\/?page_id=363"},"modified":"2026-04-12T11:30:01","modified_gmt":"2026-04-12T02:30:01","slug":"researc","status":"publish","type":"page","link":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/researc\/","title":{"rendered":"\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"

2026 (\u8ad6\u6587)<\/h2>\n
    \n
  1. Akiba H, Nakashima K, Ichinose T, Watanabe H, Ono M
    \nInfluence of the binding valency of anti-HER2 biparatopic antibodies on biodistribution in an SK-OV-3 tumor xenograft model
    \n<\/span>Mol<\/em><\/span><\/span><\/span>. Pharm.<\/span><\/em> in press<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span>DOI: 10.1021\/acs.molpharmaceut.5c01515<\/span><\/span><\/span><\/li>\n
  2. Hasegawa T, Nakashima K, Watanabe H, Ono M
    \nDual pharmacokinetic modifier strategy for synergistically enhanced tumor accumulation of PSMA-targeting radioligand
    \n<\/span>Chem<\/em><\/span><\/span><\/span>. Commun.<\/span><\/em> 62 4851-4854 (2026)<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span>DOI: 10.1039\/d5cc06620d<\/span><\/span><\/span><\/li>\n
  3. Nakashima K, Ono M
    \nReply to the letter to the editor from Drs. Huang and Chen
    \n<\/span><\/span><\/span>Ann. Nucl. Med. <\/em>in press
    \nDOI: 10.1007\/s12149-026-02167-3<\/span><\/span><\/span><\/span><\/li>\n
  4. Saito K, Watanabe H, Nakashima K, Chiba Y, Hashimoto K, Fujino S, Kawauchi Y, Saeki H, Takashima N, Kawabata M, Ono M
    \nPreclinical evaluation of novel 177<\/sup>Lu-labeled fibroblast activation protein inhibitor with albumin binder for radioligand therapy
    \n<\/span><\/span><\/span>Ann. Nucl. Med. <\/em>in press
    \nDOI: 10.1007\/s12149-026-02167-3<\/span><\/span><\/span><\/span><\/li>\n
  5. Okuyama C, Oishi N, Ishizu K, Hasegawa H, Ito M, Fujita Y, Kusano K, Okina T, Kagawa S, Watanabe H, Higashi T, Yamauchi H, Ono M
    \nA new amyloid PET evaluation method using separated gray-matter histogram based on three-component model
    \n<\/span><\/span><\/span>Ann. Nucl. Med. <\/em>in press
    \nDOI: 10.1007\/s12149-026-02157-5<\/span><\/span><\/span><\/span><\/li>\n
  6. Yamane T, Kazuta N, Nakashima K, Watanabe H, Ono M
    \nEffect of Structural Alteration in Albumin Binder Moiety on Tumor Accumulation of Somatostatin Receptor 2\u2011Targeted Radioligands
    \n<\/span><\/span><\/span>ACS Pharmacol. Transl. Sci. <\/em>9(2) 348-358 (2026)
    \nDOI: 10.1021\/acsptsci.5c00591<\/span><\/span><\/span><\/span>
    \n<\/span><\/span><\/span><\/p>\n

    \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n<\/li>\n<\/ol>\n

    2026 (\u5b66\u4f1a\u767a\u8868\u306a\u3069)<\/h2>\n
      \n
    1. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u51dd\u96c6\u4f53\u306e\u6838\u533b\u5b66\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u304a\u3088\u3073\u5149\u9178\u7d20\u5316\u3092\u76ee\u7684\u3068\u3057\u305f18<\/sup>F\u6a19\u8b58\u30d0\u30a4\u30c1\u30aa\u30d5\u30a7\u30f3\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    2. \u751a\u7530 \u6d38\u5e0c, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u524d\u7acb\u817a\u7279\u7570\u7684\u819c\u6297\u539f\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u30dd\u30ea\u30a8\u30c1\u30ec\u30f3\u30b0\u30ea\u30b3\u30fc\u30eb\u542b\u6709\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span>
      \n<\/span><\/span><\/li>\n
    3. \u5c71\u672c \u8cb4\u88d5, \u4e2d\u5cf6 \u4e00\u78e8, \u6570\u591a \u4f38\u7d00, \u6a4b\u672c \u548c\u5e78, \u5343\u8449 \u60a0\u4ecb, \u85e4\u91ce \u96bc\u8f14, \u6cb3\u5185 \u5e78\u6b63, \u4f50\u4f2f \u79c0\u4e5f, \u9ad8\u5cf6 \u76f4\u8cb4, \u5ddd\u7aef \u65b9\u5b50, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u30b3\u30ec\u30b7\u30b9\u30c8\u30ad\u30cb\u30f32\u53d7\u5bb9\u4f53\u6a19\u7684\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u306b\u8cc7\u3059\u308b\u65b0\u898f111<\/sup>In\/177<\/sup>Lu\u6a19\u8b58\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    4. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u524d\u7acb\u817a\u304c\u3093\u3092\u6a19\u7684\u3068\u3057\u305f\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u542b\u6709\u65b0\u898f\u30d8\u30c6\u30ed\u30c0\u30a4\u30de\u30fc\u578b\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    5. \u67cf\u5c71 \u9678\u6597, \u6e21\u908a \u88d5\u4e4b, \u8d64\u5742 \u8cb4\u6d69, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u30aa\u30fc\u30b8\u30a7\u96fb\u5b50\u304c\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u51dd\u96c6\u904e\u7a0b\u306b\u53ca\u307c\u3059\u4f5c\u7528\u306e\u8a55\u4fa1
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    6. \u5c71\u6839 \u62d3\u771f, \u4e2d\u5cf6 \u4e00\u78e8, \u6570\u591a \u4f38\u7d00, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u795e\u7d4c\u5185\u5206\u6ccc\u816b\u760d\u306e\u8a3a\u65ad\u30fb\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u4e8c\u4fa1\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u542b\u6709\u653e\u5c04\u6027\u30ea\u30ac\u30f3\u30c9\u306e\u958b\u767a
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    7. \u5927\u6d25 \u660c\u7fa9, \u9f4b\u85e4 \u6d69\u8f14, \u4e2d\u5cf6 \u4e00\u78e8, \u85e4\u672c \u88d5\u4e4b, \u6751\u4e0a \u660c\u53f2, \u5927\u6c5f \u4e00\u5f18, \u8c4a\u5d8b \u539a\u53f2, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u6a19\u7684\u03b1\u7dda\u6cbb\u7642\u306e\u305f\u3081\u306e\u65b0\u898f\u30cb\u30e5\u30fc\u30ed\u30c6\u30f3\u30b7\u30f3\u53d7\u5bb9\u4f531\u6a19\u7684211<\/sup>At\u6a19\u8b58\u85ac\u5264\u306e\u958b\u767a
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    8. \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, <\/span><\/span>\u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>\u304c\u3093\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u3092\u6307\u5411\u3057\u305fantibody-radionuclide conjugate\u306e\u5206\u5b50\u8a2d\u8a08\u6226\u7565
      \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c146\u5e74\u4f1a (\u5927\u962a) 2026\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
    9. \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
      \n<\/span><\/span>Research on Radiopharmaceutical Chemistry for Theranostics
      \nSubstantia Life Science \u7814\u7a76\u4ea4\u6d41\u4f1a\uff08\u4eac\u90fd\uff092026\u5e743\u67083\u65e5<\/span><\/span><\/span><\/li>\n<\/ol>\n

      \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

      2025 (\u8ad6\u6587)<\/h2>\n
        \n
      1. Nakashima K, Yamaguchi K, Saito K, Watanabe H, Ono M.
        \nNovel bivalent albumin binder for enhanced tumor retention of fibroblast activation protein-targeted radioligand
        \n<\/span>Chem<\/em><\/span><\/span><\/span>. Commun.<\/span><\/em> 61(96) 19072-19075 (2025)<\/span><\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI: <\/span><\/span><\/span>10.1039\/d5cc05231a<\/span><\/span><\/span><\/span><\/li>\n
      2. Watanabe H, Saito H, Nakashima K, Ono M.
        \nStructure-Activity Relationships of Azaquinazolinone Derivatives as 18<\/sup>F-Labeled PET Probes Targeting Ghrelin Receptors
        \n<\/span>J. Med. Chem.<\/span><\/em> 68(21) 22288-22300 (2025)<\/span><\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI: <\/span><\/span><\/span>10.1021\/acs.jmedchem.5c01070<\/span><\/span><\/span><\/span><\/li>\n
      3. Akasaka T, Watanabe H, Ono M.
        \nNovel BODIPY-Based Fluorescent Probes with Improved Aqueous Solubility for Selective Detection of Soluble A\u03b2 Aggregates<\/span>
        \n<\/span>ACS Chem. Neurosci.<\/em> 16(21) 4257-4266 (2025)
        \n<\/em>DOI: 10.1021\/acschemneuro.5c00525<\/span><\/span><\/span><\/span><\/li>\n
      4. Nakashima K, Jinda H, Shimohara H, Watanabe H, Ono M.<\/span>
        \n<\/span>Control of pharmacokinetics of radioimmunoconjugates using chelating agents containing poly(ethylene glycol)
        \n<\/span><\/span>J. Control. Release <\/em>388, 114293 (2025)<\/span><\/span>
        \n<\/span>DOI: 10.1016\/j.jconrel.2025.114293<\/span><\/span><\/li>\n
      5. Saito K, Watanabe H, Yamaguchi K, Nakashima K, Ono M.<\/span>
        \n<\/span>Impact of Albumin-Binding Moieties on Structure-Affinity-Pharmacokinetic Relationships of Novel FAP-Targeting Radioligands
        \n<\/span><\/span>Mol. Pharm.<\/em> 22(10) 5989-5998 (2025)<\/span><\/span>
        \n<\/span>DOI: 10.1021\/acs.molpharmaceut.5c00631<\/span><\/span><\/li>\n
      6. Kashiyama R, Watanabe H, Akasaka T, Fujimoto H, Murakami M, Ooe K, Toyoshima A, Nakashima K, Ono M.<\/span>
        \n<\/span>Feasibility of targeted alpha therapy for Alzheimer\u2019s disease using 211<\/sup>At\u2010labeled agent targeting amyloid\u2010\u03b2 aggregates
        \n<\/span><\/span>Ann. Nucl. Med. <\/em>39(12) 1319-1325 (2025)<\/span><\/span> <\/span><\/span>
        \n<\/span><\/span><\/span>DOI: 10.1007\/s12149-025-02095-8<\/span><\/span><\/span><\/li>\n
      7. Kazuta N, Nakashima K, Watanabe H, Ono M
        \nDevelopment of Novel Integrin \u03b1v\u03b23-targeted Radioligand for Enhanced Tumor Accumulation
        \n<\/span>ACS Med. Chem. Lett.<\/em> 16(7) 1346-1353 (2025)<\/span><\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI: 10.1021\/acsmedchemlett.5c00231<\/span><\/span><\/span><\/li>\n
      8. Hasegawa T, Nakashima K, Tarumizu Y, Tada M, Maya Y, Watanabe H, Ono M.
        \nDevelopment of Novel Radiotheranostic Ligand with Positively Charged Unit Targeting Prostate-Specific Membrane Antigen
        \n<\/span>J. Med. Chem<\/em><\/span><\/span><\/span>. <\/em>68(10) 10190-10202 (2025)<\/span><\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI: <\/span><\/span><\/span>10.1021\/acs.jmedchem.5c00370<\/span><\/span><\/span><\/span><\/li>\n
      9. Tsuchihashi S, Nakashima K, Watanabe H, Ono M.
        \nDevelopment of Novel Gastrin-Releasing Peptide Receptor-targeted Radioligand with Albumin Binder to Improve Accumulation in Tumor
        \n<\/span>ACS Med. Chem. Lett. <\/em>16(5) 797-803 (2025)<\/span><\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI:\u00a0<\/span><\/span><\/span>10.1021\/acsmedchemlett.5c00032<\/span><\/span><\/span><\/span><\/li>\n
      10. Nakashima K, Ichinose T, Watanabe H, Ono M.<\/span>
        \n<\/span>Comparison of Carbonic Anhydrase-IX-targeted Trifunctional Radioligands between Linear- and Branched-chain Arrangements
        \n<\/span>Front. Nucl. Med.<\/em> 5 1583027 (2025)<\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI: 10.3389\/fnume.2025.1585027<\/span><\/span><\/span><\/li>\n
      11. Saito K, Watanabe H, Nakashima K, Ono M.<\/span>
        \n<\/span>Preclinical Characterization of Novel FAP-2286-Based Radioligand with Albumin Binder for Improved Tumor Retention
        \n<\/span><\/span>ACS Med. Chem. Lett.<\/em> 16(4) 596-601 (2025)<\/span><\/span><\/span>
        \n<\/span><\/span><\/span>DOI: 10.1021\/acsmedchemlett.4c00630<\/span><\/span><\/span><\/li>\n
      12. Kashiyama R, Watanabe H, Akasaka T, Ono M.<\/span>
        \n<\/span>Novel amyloid-\u03b2 oligomer-targeted fluorescent probes by introducing branched chain into push-pull type dye
        \n<\/span><\/span>Dyes Pigm. <\/em>236 112680 (2025)\u00a0<\/span><\/span>
        \n<\/span><\/span><\/span>DOI: <\/span><\/span>10.1016\/j.dyepig.2025.112680<\/span><\/li>\n
      13. Okuyama C, Inuzuka Y, Takeuchi Y, Asagoe K, Kagawa S, Ito M, Kusano K, Fujita Y, Watanabe H, Ono M, Higashi T.<\/span>
        \n<\/span>Imaging of cardiac amyloidosis using dynamic 18<\/sup>F-FPYBF-2 positron emission tomography<\/span><\/span>
        \n<\/span><\/span>Ann. Nucl. Med. <\/em>39(4) 398-403 (2025)
        \n<\/span>DOI: 10.1007\/s12149-024-02010-7<\/span><\/span><\/span><\/li>\n
      14. Nakashima K, Shimohara H, Watanabe H, Ono M.<\/span>
        \n<\/span>Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent
        \n<\/span><\/span>Ann. Nucl. Med.<\/em> 39(4) 323-333 (2025)
        \n<\/span>DOI: 10.1007\/s12149-024-02003-6<\/span><\/span><\/li>\n
      15. Kazuta N, Nakashima K, Tarumizu Y, Sato T, Maya Y, Watanabe H, Ono M.<\/span>
        \n<\/span>Novel Radiotheranostic Ligands Targeting Prostate-Specific Membrane Antigen Based on Dual Linker Approach
        \n<\/span><\/span>Mol. Pharm. <\/em>22(1) 377-386 (2025)\u00a0<\/em>
        \n<\/span>DOI: 10.1021\/acs.molpharmaceut.4c00974<\/span><\/span><\/li>\n<\/ol>\n

        \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

        2025 (\u5b66\u4f1a\u767a\u8868\u306a\u3069)<\/h2>\n
          \n
        1. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u4e2d\u5cf6 \u4e00\u78e8, \u5343\u8449 \u60a0\u4ecb, \u6a4b\u672c \u548c\u5e78, \u85e4\u91ce \u96bc\u8f14, \u6cb3\u5185 \u5e78\u6b63, \u4f50\u4f2f \u79c0\u4e5f, \u9ad8\u5cf6 \u76f4\u8cb4, \u5ddd\u7aef \u65b9\u5b50, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>FAP\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f111<\/sup>In\/177<\/sup>Lu\u6a19\u8b58\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a
          \n\u7b2c3\u56de\u77ed\u5bff\u547dRI\u5229\u7528\u7814\u7a76\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff08\u5bae\u57ce\uff092025\u5e7411\u670828\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        2. \u67cf\u5c71 \u9678\u6597, \u6e21\u908a \u88d5\u4e4b, \u8d64\u5742 \u8cb4\u6d69, \u85e4\u672c \u88d5\u4e4b, \u6751\u4e0a \u660c\u53f2, \u5927\u6c5f \u4e00\u5f18, \u8c4a\u5d8b \u539a\u53f2, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>211<\/sup>At<\/span><\/span><\/span><\/span><\/span>\u6a19\u8b58\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u30d7\u30ed\u30fc\u30d6\u306e\u5408\u6210\u3068\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u6cbb\u7642\u7528\u85ac\u5264\u3068\u3057\u3066\u306e\u57fa\u790e\u7684\u8a55\u4fa1
          \n\u7b2c3\u56de\u77ed\u5bff\u547dRI\u5229\u7528\u7814\u7a76\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff08\u5bae\u57ce\uff092025\u5e7411\u670828\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        3. \u6e21\u908a \u88d5\u4e4b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u8133\u5185\u30aa\u30ec\u30ad\u30b7\u30f3\u53d7\u5bb9\u4f53\u3092\u6a19\u7684\u3068\u3057\u305fPET\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\u7814\u7a76
          \n\u7b2c3\u56de\u77ed\u5bff\u547dRI\u5229\u7528\u7814\u7a76\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff08\u5bae\u57ce\uff092025\u5e7411\u670828\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        4. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u4e2d\u5cf6 \u4e00\u78e8, \u5343\u8449 \u60a0\u4ecb, \u6a4b\u672c \u548c\u5e78, \u85e4\u91ce \u96bc\u8f14, \u6cb3\u5185 \u5e78\u6b63, \u4f50\u4f2f \u79c0\u4e5f, \u9ad8\u5cf6 \u76f4\u8cb4, \u5ddd\u7aef \u65b9\u5b50, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u7dda\u7dad\u82bd\u7d30\u80de\u6d3b\u6027\u5316\u30bf\u30f3\u30d1\u30af\u8cea\u3092\u6a19\u7684\u3068\u3057\u305f177<\/sup>Lu\u6a19\u8b58\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u7d50\u5408\u578b\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        5. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u524d\u7acb\u817a\u304c\u3093\u306b\u304a\u3051\u308bPSMA\u304a\u3088\u3073GRPR\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u653e\u5c04\u6a19\u8b58\u30d8\u30c6\u30ed\u30c0\u30a4\u30de\u30fc\u306e\u958b\u767a
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        6. \u6570\u591a \u4f38\u7d00, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u65b0\u898f\u30ea\u30f3\u30ab\u30fc\u6280\u8853\u3092\u7528\u3044\u305f\u30a4\u30f3\u30c6\u30b0\u30ea\u30f3\u03b1v\u03b23\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u816b\u760d\u96c6\u7a4d\u6027\u306b\u95a2\u3059\u308b\u691c\u8a0e
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        7. \u5c71\u672c \u8cb4\u88d5, \u4e2d\u5cf6 \u4e00\u78e8, \u6570\u591a \u4f38\u7d00, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u30b3\u30ec\u30b7\u30b9\u30c8\u30ad\u30cb\u30f32\u53d7\u5bb9\u4f53\u3092\u6a19\u7684\u3068\u3057\u305f\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u542b\u6709\u653e\u5c04\u6027\u30ea\u30ac\u30f3\u30c9\u306e\u958b\u767a
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        8. \u5c71\u6839 \u62d3\u771f, \u6570\u591a \u4f38\u7d00, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u30a2\u30eb\u30d6\u30df\u30f3\u7d50\u5408\u6027\u306b\u7740\u76ee\u3057\u305f\u65b0\u898fSSTR2\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        9. \u9577\u8c37\u5ddd \u62d3\u771f, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>2\u7a2e\u306e\u4f53\u5185\u52d5\u614b\u5236\u5fa1\u30e6\u30cb\u30c3\u30c8\u3092\u7528\u3044\u305f\u65b0\u898fPSMA\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        10. \u67cf\u5c71 \u9678\u6597, \u6e21\u908a \u88d5\u4e4b, \u8d64\u5742 \u8cb4\u6d69, \u85e4\u672c \u88d5\u4e4b, \u6751\u4e0a \u660c\u53f2, \u5927\u6c5f \u4e00\u5f18, \u8c4a\u5d8b \u539a\u53f2, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u306e\u6a19\u7684\u03b1\u7dda\u6cbb\u7642\u7528\u85ac\u5264\u958b\u767a\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u7814\u7a76
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        11. \u4e2d\u5cf6 \u4e00\u78e8<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        12. \u6e21\u908a \u88d5\u4e4b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>Development of bimodal agents for auger electron and photodynamic combination therapy
          \n\u7b2c65\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff092025\u5e7411\u670813\u65e5\u301c15\u65e5<\/span><\/span><\/span><\/span><\/li>\n
        13. \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u30a2\u30eb\u30d6\u30df\u30f3\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u3092\u6d3b\u7528\u3057\u305f\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a\u6226\u7565(\u7279\u5225\u8b1b\u6f14)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c32\u56de \u65e5\u672c\u8840\u6db2\u4ee3\u66ff\u7269\u5b66\u4f1a\u5e74\u6b21\u5927\u4f1a (\u718a\u672c) 2025\u5e7410\u670830\u65e5, 31\u65e5<\/span><\/span><\/span><\/li>\n
        14. \u8fbb \u7965\u592a\u90ce, \u5c0f\u91ce \u6b63\u535a, \u4e0a\u5e73 \u6b63\u9053, \u6797 \u660e\u5e0c\u7537<\/span>
          \n<\/span><\/span><\/span><\/span>SKM9-2\u3092\u7528\u3044\u305f\u4e2d\u76ae\u816b\u306b\u5bfe\u3059\u308bRI\u6a19\u8b58\u6297\u4f53\u533b\u85ac\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c6\u56de \u65e5\u672c\u77f3\u7dbf\u30fb\u4e2d\u76ae\u816b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (\u5175\u5eab) 2025\u5e7410\u67084\u65e5, 5\u65e5<\/span><\/span><\/span><\/li>\n
        15. \u5c71\u6839 \u62d3\u771f, \u6570\u591a \u4f38\u7d00, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u30bd\u30de\u30c8\u30b9\u30bf\u30c1\u30f3\u53d7\u5bb9\u4f532\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u542b\u6709\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c75\u56de \u65e5\u672c\u85ac\u5b66\u4f1a\u95a2\u897f\u652f\u90e8\u7dcf\u4f1a\u30fb\u5927\u4f1a (\u4eac\u90fd) 2025\u5e7410\u67084\u65e5<\/span><\/span><\/span><\/li>\n
        16. \u5927\u6d25 \u660c\u7fa9, \u9f4b\u85e4 \u6d69\u8f14, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u30cb\u30e5\u30fc\u30ed\u30c6\u30f3\u30b7\u30f3\u53d7\u5bb9\u4f531\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u653e\u5c04\u6027\u30e8\u30a6\u7d20\u6a19\u8b58\u85ac\u5264\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c75\u56de \u65e5\u672c\u85ac\u5b66\u4f1a\u95a2\u897f\u652f\u90e8\u7dcf\u4f1a\u30fb\u5927\u4f1a (\u4eac\u90fd) 2025\u5e7410\u67084\u65e5<\/span><\/span><\/span><\/li>\n
        17. \u2ed1\u8c37\u5ddd \u62d3\u771f, \u4e2d\u5cf6 \u4e00\u78e8, \u5782\u6c34 \u52c7\u592a, \u591a\u7530 \u5321\u5229, \u771e\u77e2 \u5553\u53f2, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a\u00a0<\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span>\u6b63\u96fb\u8377\u30e6\u30cb\u30c3\u30c8\u3092\u6709\u3059\u308b\u65b0\u898fPSMA\u6a19\u7684\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c8\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c24<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u798f\u5ca1)\u00a0 <\/span>2025\u5e749\u67086\u65e5<\/span><\/span><\/li>\n
        18. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u5c71\u53e3 \u6075\u8056, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span>\u816b\u760d\u96c6\u7a4d\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898fFAP\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c8\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c24<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u798f\u5ca1)\u00a0 <\/span>2025\u5e749\u67086\u65e5<\/span><\/span><\/li>\n
        19. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u9f4b\u85e4 \u6d69\u8f14, \u6a4b\u672c \u548c\u5e78, \u5343\u8449 \u60a0\u4ecb, \u85e4\u91ce \u96bc\u8f14, \u6cb3\u5185 \u5e78\u6b63, \u4f50\u4f2f \u79c0\u4e5f, \u9ad8\u5cf6 \u76f4\u8cb4, \u5ddd\u7aef \u65b9\u5b50, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span>\u304c\u3093\u306e\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898fGRPR\u6a19\u7684111<\/sup>In\/177<\/sup>Lu\u6a19\u8b58\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c8\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c24<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u798f\u5ca1)\u00a0 <\/span>2025\u5e749\u67086\u65e5<\/span><\/span><\/li>\n
        20. Nobuki Kazuta, Shohei Tsuchihashi, Hiroyuki Watanabe, Kazuma Nakashima, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span>Impact of albumin-binding on tumor accumulation of PSMA-targeted radioligands<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c5\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2025\u5e749\u67083\u65e5, 4\u65e5<\/span><\/span><\/li>\n
        21. Kosuke Saito, Hiroyuki Watanabe, Keisei Yamaguchi, Kazuma Nakashima, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span>Novel radioligands for fibroblast activation protein utilizing albumin binder<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c5\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2025\u5e749\u67083\u65e5, 4\u65e5<\/span><\/span><\/li>\n
        22. Shohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
          \n<\/span><\/span><\/span>Development of novel radiolabeled agent targeting gastrin- releasing peptide receptor for enhanced tumor accumulation<\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c5\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2025\u5e749\u67083\u65e5, 4\u65e5<\/span><\/span><\/li>\n
        23. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
          \n\u672a\u6765\u3092\u62d3\u304f\u85ac\u5b66 \u301c\u304c\u3093\u3068\u8a8d\u77e5\u75c7\u306e\u65b0\u3057\u3044\u85ac\u301c\u3000(\u6559\u54e1\u8b1b\u6f14)<\/span><\/span><\/span>
          \n\u4eac\u90fd\u5927\u5b66 mini\u30aa\u30fc\u30d7\u30f3\u30ad\u30e3\u30f3\u30d1\u30b92025 in TOKYO 2025\u5e748\u670831\u65e5<\/span><\/span><\/li>\n
        24. \u751a\u7530 \u6d38\u5e0c, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u653e\u5c04\u6027\u85ac\u5264\u306e\u304c\u3093\u7d30\u80de\u5185\u6ede\u7559\u6027\u306e\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u30ab\u30c6\u30d7\u30b7\u30f3B\u7d50\u5408\u6027\u30ad\u30ec\u30fc\u30c8\u30ea\u30f3\u30ab\u30fc\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7523\u5b66\u5408\u540c\u535a\u58eb\u767a\u8868\u4ea4\u6d41\u4f1a\uff08\u4eac\u90fd\uff092025\u5e748\u670829\u65e5<\/span><\/span><\/span><\/li>\n
        25. \u4e2d\u91ce \u5927\u6a39, \u6e21\u908a \u88d5\u4e4b, \u9f4b\u85e4 \u6d69\u8f14, \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u30bf\u30f3\u30d1\u30af\u8cea\u30fb\u30da\u30d7\u30c1\u30c9\u306e\u30c1\u30ed\u30b7\u30f3\u7279\u7570\u7684RI\u6a19\u8b58\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u4e8c\u5b98\u80fd\u6027\u30ad\u30ec\u30fc\u30c8\u8a66\u85ac\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7523\u5b66\u5408\u540c\u535a\u58eb\u767a\u8868\u4ea4\u6d41\u4f1a\uff08\u4eac\u90fd\uff092025\u5e748\u670829\u65e5<\/span><\/span><\/span><\/li>\n
        26. \u6dfa\u96db \u7a42\u4e43\u82b1, \u4e2d\u5cf6 \u4e00\u78e8, \u9577\u8c37\u5ddd \u62d3\u771f, \u00a0\u85e4\u672c \u88d5\u4e4b, \u6751\u4e0a \u660c\u53f2, \u5927\u6c5f \u4e00\u5f18, \u8c4a\u5d8b \u539a\u53f2, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u524d\u7acb\u817a\u7279\u7570\u7684\u819c\u6297\u539f\u3092\u6a19\u7684\u3068\u3057\u305f 211<\/sup>At\u6a19\u8b58\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u542b\u6709\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c22\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0\uff08\u798f\u5ca1\uff092025\u5e748\u670821\u65e5, 22\u65e5<\/span><\/span><\/span><\/li>\n
        27. \u7530\u4e2d \u771f\u592e, \u6570\u591a \u4f38\u7d00, \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
          \n<\/span><\/span><\/span><\/span>\u304c\u3093\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u4f53\u5185\u52d5\u614b\u5236\u5fa1\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u8102\u80aa\u9178\u578b\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u306e\u63a2\u7d22<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \n\u7b2c22\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0\uff08\u798f\u5ca1\uff092025\u5e748\u670821\u65e5, 22\u65e5<\/span><\/span><\/span><\/li>\n
        28. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
          \n\u672a\u6765\u3092\u62d3\u304f\u85ac\u5b66 \u301c\u304c\u3093\u3068\u8a8d\u77e5\u75c7\u306e\u65b0\u3057\u3044\u85ac\u301c\u3000(\u6559\u54e1\u8b1b\u6f14)<\/span><\/span><\/span>
          \n\u4eac\u90fd\u5927\u5b66 mini\u30aa\u30fc\u30d7\u30f3\u30ad\u30e3\u30f3\u30d1\u30b92025 in NAGOYA 2025\u5e748\u670818\u65e5<\/span><\/span><\/li>\n
        29. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
          \n\u85ac\u5b66\u3067\u62d3\u304f\u672a\u6765\u306e\u304c\u3093\u6cbb\u7642 \u301c\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u3078\u306e\u6311\u6226\u301c\u3000(\u6a21\u64ec\u6388\u696d)<\/span><\/span><\/span>
          \n\u4eac\u90fd\u5927\u5b66\u85ac\u5b66\u90e8\u30aa\u30fc\u30d7\u30f3\u30ad\u30e3\u30f3\u30d1\u30b9 2025\u5e748\u67087\u65e5<\/span><\/span><\/li>\n
        30. Shohei Tsuchihashi, Kazuma Nakashima, Hiroki Jinda, Hiroyuki Watanabe, Masahiro Ono<\/span>
          \nRadiotheranostics via Chemical Modulation of Pharmacokinetics<\/span><\/span><\/span>
          \n\u4eac\u5927\u9662\u85ac-\u533b\u85ac\u57fa\u76e4\u7814\u9023\u643a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 (\u4eac\u90fd) 2025\u5e747\u670825\u65e5<\/span><\/span><\/li>\n
        31. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
          \n\u6c34\u6eb6\u6027BODIPY\u8a98\u5c0e\u4f53\u306eA\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u86cd\u5149\u30d7\u30ed\u30fc\u30d6\u3068\u3057\u3066\u306e\u6709\u7528\u6027\u8a55\u4fa1<\/span><\/span><\/span>
          \n\u7b2c19\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u798f\u4e95) 2025\u5e745\u670829\u65e5, 30\u65e5<\/span><\/span><\/li>\n
        32. \u6e21\u908a \u88d5\u4e4b, \u9f4b\u85e4 \u6674\u9999, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
          \n\u30a2\u30b6\u30ad\u30ca\u30be\u30ea\u30ce\u30f3\u9aa8\u683c\u3092\u57fa\u76e4\u3068\u3057\u305f\u30b0\u30ec\u30ea\u30f3\u53d7\u5bb9\u4f53\u6a19\u7684PET\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
          \n\u7b2c19\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u798f\u4e95) 2025\u5e745\u670829\u65e5, 30\u65e5<\/span><\/span><\/li>\n
        33. Kosuke Saito, Hiroyuki Watanabe, Kazuma Nakashima, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \nDevelopment of novel fibroblast activation protein-targeting radioligand with albumin binder to improve tumor retention<\/span>
          \n<\/span><\/span><\/span><\/span>The 26th International Symposium on Radiopharmaceutical Sciences (Gold Coast, Australia) May 11-15, 2025<\/span><\/span><\/span><\/li>\n
        34. Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \nNovel strategy using PEGylated chelating agents to enhance tumor retention of radioimmunoconjugates\u00a0<\/span>
          \n<\/span><\/span><\/span><\/span>The 26th International Symposium on Radiopharmaceutical Sciences (Gold Coast, Australia) May 11-15, 2025<\/span><\/span><\/span><\/li>\n
        35. Rikuto Kashiyama, Hiroyuki Watanabe, Takahiro Akasaka, Hiroyuki Fujimoto, Masashi Murakami, Kazuhiro Ooe, Atsushi Toyoshima, Kazuma Nakashima, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
          \nPotential of 211<\/sup>At-Labeled Amyloid-\u03b2 Binding Agent for Targeted Alpha Therapy in Alzheimer\u2019s Disease\u00a0<\/span>
          \n<\/span><\/span><\/span><\/span>The 26th International Symposium on Radiopharmaceutical Sciences (Gold Coast, Australia) May 11-15, 2025<\/span><\/span><\/span><\/li>\n
        36. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
          \nPET\u691c\u67fb\u85ac\u306e\u88fd\u9020\u30fb\u7ba1\u7406 (PET\u7814\u4fee\u30bb\u30df\u30ca\u30fc)<\/span><\/span><\/span>
          \n\u7b2c25\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u6625\u5b63\u5927\u4f1a (\u30aa\u30f3\u30e9\u30a4\u30f3) 2025\u5e744\u670824\u65e5\u301c6\u67083\u65e5<\/span><\/span><\/li>\n
        37. \u9577\u8c37\u5ddd \u62d3\u771f, \u4e2d\u5cf6 \u4e00\u78e8, \u5782\u6c34 \u52c7\u592a, \u591a\u7530 \u5321\u5229, \u5c0d\u99ac \u7406\u5f66, \u771e\u77e2 \u5553\u53f2, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
          \n\u6b63\u96fb\u8377\u30e6\u30cb\u30c3\u30c8\u3092\u6709\u3059\u308b111<\/sup>In\/225<\/sup>Ac\u6a19\u8b58PSMA\u6a19\u7684\u85ac\u5264\u3092\u7528\u3044\u305f\u304c\u3093\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        38. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u5c71\u53e3 \u6075\u8056, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a
          \n\u7dda\u7dad\u82bd\u7d30\u80de\u6d3b\u6027\u5316\u30bf\u30f3\u30d1\u30af\u8cea\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u7d50\u5408\u578b\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        39. \u6dfa\u96db \u7a42\u4e43\u82b1, \u4e2d\u5cf6 \u4e00\u78e8, \u9577\u8c37\u5ddd \u62d3\u771f, \u85e4\u672c \u88d5\u4e4b, \u6751\u4e0a \u660c\u53f2, \u5927\u6c5f \u4e00\u5f18, \u8c4a\u5d8b \u539a\u53f2, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
          \n\u65b0\u898f211<\/sup>At\u6a19\u8b58PSMA\u6a19\u7684\u85ac\u5264\u306e\u958b\u767a\u3092\u76ee\u7684\u3068\u3057\u305f125<\/sup>I\u6a19\u8b58\u4f53\u306b\u3088\u308b\u57fa\u790e\u7684\u8a55\u4fa1<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        40. \u6570\u591a \u4f38\u7d00, \u4e2d\u5cf6 \u4e00\u78e8, \u5782\u6c34 \u52c7\u592a, \u771e\u77e2 \u5553\u53f2, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
          \n\u65b0\u898f\u30ea\u30f3\u30ab\u30fc\u6280\u8853\u3092\u5229\u7528\u3057\u305f111<\/sup>In\/225<\/sup>Ac\u6a19\u8b58PSMA\u6a19\u7684\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        41. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
          \n\u30d0\u30a4\u30aa\u30a2\u30c3\u30bb\u30a4\u3078\u306e\u5fdc\u7528\u3092\u53ef\u80fd\u3068\u3059\u308b\u6c34\u6eb6\u6027\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u86cd\u5149\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        42. \u67cf\u5c71 \u9678\u6597, \u6e21\u908a \u88d5\u4e4b, \u8d64\u5742 \u8cb4\u6d69, \u85e4\u672c \u88d5\u4e4b, \u6751\u4e0a \u660c\u53f2, \u5927\u6c5f \u4e00\u5f18, \u8c4a\u5d8b \u539a\u53f2, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a
          \n\u9ad8LET\u8377\u96fb\u7c92\u5b50\u7dda\u306b\u3088\u308b\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u51dd\u96c6\u6291\u5236\u4f5c\u7528\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u8a55\u4fa1<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        43. \u5c71\u6839 \u62d3\u771f, \u6570\u591a \u4f38\u7d00, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
          \n\u816b\u760d\u6ede\u7559\u6027\u306e\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u30bd\u30de\u30c8\u30b9\u30bf\u30c1\u30f3\u53d7\u5bb9\u4f532\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c145\u5e74\u4f1a (\u798f\u5ca1) 2025\u5e743\u670826\u65e5\u301c29\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
        44. \u6e21\u908a \u88d5\u4e4b<\/span>
          \n<\/span>\u304c\u3093\u306e\u653e\u5c04\u7dda\u5185\u7528\u7642\u6cd5\u306e\u767a\u5c55\u306b\u5411\u3051\u305f\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u958b\u767a<\/span><\/span><\/span>
          \n\u7b2c13\u56de BRIGHT symposium<\/span><\/span><\/span>\uff08\u5fb3\u5cf6)\u00a0 <\/span>2025\u5e742\u67085\u65e5<\/span><\/span><\/li>\n<\/ol>\n

          \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

          2024 (\u8ad6\u6587)<\/h2>\n
            \n
          1. Ishizaka Y, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Structure-Affinity-Pharmacokinetics Relationships of Novel <\/span>18<\/sup>F\u2010Labeled 1,4-Diazepane Derivatives for Orexin 1 Receptor Imaging<\/span>
            \n<\/span><\/span><\/span><\/span>J. Med. Chem. <\/em>67(21) 18781-18793 (2024)<\/span>
            \n<\/span>DOI: <\/span>10.1021\/acs.jmedchem.4c01090<\/span><\/span><\/li>\n
          2. Nakano D, Watanabe H, Saito K, Ono M.<\/span><\/span>
            \n<\/span><\/span>A Novel Bifunctional Chelating Agent for Tyrosine-Specific Radiolabeling of Peptides and Proteins<\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Bioconjug. Chem. <\/em>35(10) 1577-1586 (2024)
            \n<\/span>DOI: 10.1021\/acs.bioconjchem.4c00363<\/span><\/span><\/span><\/li>\n
          3. Yamaguchi K, Kazuta N, Tsuchihashi S, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Structure-affinity-pharmacokinetics relationships of 111<\/sup>In-labeled PSMA-targeted ligands with different albumin binders<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Nucl. Med. Biol.<\/em> 138-139 108945 (2024)
            \n<\/span>DOI: 10.1016\/j.nucmedbio.2024.108945<\/span><\/span><\/span><\/li>\n
          4. Jinda H, Watanabe H, Nakashima K, Ono M.<\/span><\/span>
            \n<\/span><\/span>Application of microfluidic devices for automated two-step radiolabeling of antibodies<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span>J. Labelled Comp. Radiopharm<\/em>. 67(10) 341-348 (2024)
            \n<\/span>DOI: 10.1002\/jlcr.4119<\/span><\/span><\/span><\/span><\/li>\n
          5. Shimizu Y, Ando M, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Novel technetium-99m-labeled bivalent PSMA-targeting probe based on a hydroxamamide chelate for the diagnosis of prostate cancer<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Ann. Nucl. Med. <\/em>38(10) 847-851 (2024)
            \n<\/span><\/em>DOI: 10.1007\/s12149-024-01959-9<\/span>
            \n<\/span><\/span><\/span><\/li>\n
          6. \uff08\u516c\u793e\uff09\u65e5\u672c\u30a2\u30a4\u30bd\u30c8\u30fc\u30d7\u5354\u4f1a\u3000\u7406\u5de5\u30fb\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u90e8\u4f1a\u3000\u653e\u5c04\u7dda\u7167\u5c04\u6a19\u7684\u5206\u5b50\u63a2\u7d22\u5c02\u9580\u59d4\u54e1\u4f1a\uff08\u6e05\u91ce\u6cf0\u3001\u5c0f\u5ddd\u7f8e\u9999\u5b50\u3001\u98ef\u585a\u5927\u8f14\u3001\u5927\u5cf6\u5eb7\u5b8f\u3001\u5927\u539f\u9ebb\u5e0c\u3001\u5c0f\u91ce\u6b63\u535a\u3001\u9234\u6728\u535a\u5143\u3001\u6c38\u6d25\u5f18\u592a\u90ce\u3001\u6df5\u4e0a\u525b\u5fd7\uff09<\/span><\/span>
            \n<\/span><\/span>\u77ed\u98db\u7a0b\u653e\u5c04\u7dda\u3092\u5229\u7528\u3057\u305f\u6838\u533b\u5b66\u6cbb\u7642\u85ac\u5264\u306e\u958b\u767a\u72b6\u6cc1<\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>RADIOISOTOPES<\/em>, 73 271-290 (2024)
            \n<\/span>DOI: <\/span>10.3769\/radioisotopes.73.271<\/span><\/span><\/li>\n
          7. Kazuta N, Nakashima K, Watanabe H, Ono M.
            \nEffect of Linker Entities on Pharmacokinetics of 111<\/sup>In-Labeled Prostate-Specific Membrane Antigen-Targeting Ligands with an Albumin Binder<\/span>
            \n<\/span>ACS Pharmacol. Transl. Sci. <\/em>7(8) 2401-2413 (2024)
            \nDOI: 10.1021\/acsptsci.4c00257<\/span><\/span><\/span><\/span><\/span><\/li>\n
          8. Okuyama C, Higashi T, Ishizu K, Oishi N, Kusano K, Ito M, Kagawa S, Okina T, Suzuki N, Hasegawa H, Nagahama Y, Watanabe H, Ono M, Yamauchi H.<\/span><\/span>
            \n<\/span><\/span>New objective simple evaluation method\uff53 of amyloid PET\/CT using whole brain histogram and Top20\uff05-Map<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Ann. Nucl. Med.<\/em> 38(9) 763-773 (2024)
            \n<\/span>DOI: 10.1007\/s12149-024-01956-y<\/span><\/span><\/span><\/li>\n
          9. Akasaka T, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Combined strategies for optimizing BODIPY-based near-infrared fluorescent probe targeting A\u03b2 oligomers<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Sens. Actuators B Chem. <\/em>417 136132 (2024)
            \n<\/span>DOI: 10.1016\/j.snb.2024.136132<\/span><\/span><\/span><\/li>\n
          10. Nagashima K, Watanabe H, Akasaka T, Ono M.<\/span><\/span>
            \n<\/span><\/span>Development of triphenylmethane dyes for in vivo fluorescence imaging of A\u03b2 oligomers<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>ACS Chem. Neurosci.<\/em> 15(11) 2233-2242 (2024)
            \n<\/span>DOI: 10.1021\/acschemneuro.4c00053<\/span><\/span><\/span><\/li>\n
          11. Jinda H, Nakashima K, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Synthesis and evaluation of cathepsin B-recognizing trifunctional chelating agent to improve tumor retention of radioimmunoconjugates\u00a0<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span>J. Labelled Comp. Radiopharm<\/em>. 67(8) 995-304 (2024)\u00a0
            \n<\/span>DOI: 10.1002\/jlcr.4112<\/span><\/span><\/span><\/span><\/li>\n
          12. Onoue R, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Development of novel bi-modal agents based on near-infrared BODIPY-conjugated Hoechst derivatives for combined use in Auger electron and photodynamic cancer therapy<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>ACS Pharmacol. Transl. Sci. <\/em>7(5) 1395-1403 (2024)
            \n<\/span>DOI: 10.1021\/acsptsci.4c00035<\/span><\/span><\/span><\/li>\n
          13. Kazuta N, Tsuchihashi S, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Fundamental Evaluation Regarding the Relationship between Albumin-binding and Tumor Accumulation of PSMA-targeting Radioligands<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Ann. Nucl. Med.<\/em> 38(7) 574-583 (2024)
            \n<\/span>DOI: 10.1007\/s12149-024-01930-8<\/span><\/span><\/span><\/li>\n
          14. Tsuchihashi S, Nakashima K, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Synthesis and Evaluation of Novel Trifunctional Chelating Agents for Pretargeting Approach Using Albumin Binder to Improve Tumor Accumulation<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Nucl. Med. Biol.<\/em> 132-133 108911 (2024)
            \n<\/span>DOI: 10.1016\/j.nucmedbio.2024.108911<\/span><\/span><\/span><\/li>\n
          15. Watanabe H, Ikawa M, Kakae M, Shirakawa H, Kaneko S, Ono M.<\/span><\/span>
            \n<\/span><\/span>Synthesis and biological evaluation of radioiodinated benzoxazole and benzothiazole derivatives for imaging myelin in multiple sclerosis<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem. Lett.<\/em> 103 129691 (2024)
            \n<\/span>DOI: 10.1016\/j.bmcl.2024.129691<\/span><\/span><\/span><\/li>\n
          16. \u5c0f\u91ce \u6b63\u535a<\/span><\/span>
            \n<\/span><\/span>\u91d1\u5c5e\u30ad\u30ec\u30fc\u30c8\u3092\u57fa\u76e4\u3068\u3057\u305f111<\/sup>In\/225<\/sup>Ac\u6a19\u8b58\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>\u5927\u962a\u5927\u5b66\u653e\u5c04\u7dda\u79d1\u5b66\u57fa\u76e4\u6a5f\u69cb\u300c\u653e\u5c04\u7dda\u79d1\u5b66\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u301c\u5b5f\u5b97\u7af9\u301c2023 \u7b2c5\u53f7\u300d, 20<\/span><\/span><\/span><\/li>\n
          17. Ono M.<\/span><\/span>
            \n<\/span><\/span>Radiotheranostics Based on Chemical Control of Radioactivity Pharmacokinetics<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>YAKUGAKU ZASSHI<\/em> 144 291-297 (2024)
            \n<\/span>DOI: 10.1248\/yakushi.23-00168-3<\/span><\/span><\/span><\/li>\n
          18. Saito H, Watanabe H, Ono M.<\/span><\/span>
            \n<\/span><\/span>Synthesis and biological evaluation of novel 18<\/sup>F-labeled 2,4-diaminopyrimidine derivatives for detection of ghrelin receptor in the brain<\/span><\/span><\/span><\/span>
            \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem. Lett.<\/em> 99 129625 (2024)
            \n<\/span>DOI: 10.1016\/j.bmcl.2024.129625 <\/span><\/span><\/span><\/li>\n<\/ol>\n

            \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

            2024 (\u8457\u66f8\u7b49)<\/h2>\n
              \n
            1. \u5c0f\u91ce \u6b63\u535a\uff0c\u4e45\u4e0b \u88d5\u53f8<\/span><\/span><\/span><\/span><\/span>
              \n<\/span><\/span><\/span><\/span>\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5275\u7acb\uff16\uff10\u5468\u5e74\u8a18\u5ff5\u8a8c\u300c\u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\u300d<\/span><\/span><\/span><\/span><\/span>
              \n\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u3001\uff12\uff10\uff12\uff14\u5e74\uff11\uff10\u6708<\/li>\n<\/ol>\n

              \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

              2024 (\u5b66\u4f1a\u767a\u8868)<\/h2>\n
                \n
              1. Takuma Hasegawa, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span>Novel radioligands with tumor-residualizing properties for theranosctics of prostate cancer<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c\uff12\u56de\u77ed\u5bff\u547dRI\u5229\u7528\u7814\u7a76\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0<\/span><\/span><\/span>\uff08\u5927\u962a)\u00a0 <\/span>2024\u5e7412\u670813\u65e5\u301c14\u65e5<\/span><\/span><\/li>\n
              2. Nobuki Kazuta, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nDevelopment of novel radioligands targeting prostate-specific membrane antigen for diagnosis and therapy of prostate cancer<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th Seoul-Kyoto-Osaka Joint Symposium on Pharmaceutical Sciences for Young Scientists (Seoul, Korea) November 18-19, 2024<\/span><\/span><\/span><\/li>\n
              3. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
                \nFAP-2286\u306e\u816b\u760d\u6ede\u7559\u6027\u306e\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305fFAP\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span>
                \n\u7b2c64\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u6a2a\u6d5c\uff092024\u5e7411\u67087\u65e5\u301c9\u65e5<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n
              4. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
                \n\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u3092\u6709\u3059\u308b\u65b0\u898f\u30ac\u30b9\u30c8\u30ea\u30f3\u653e\u51fa\u30da\u30d7\u30c1\u30c9\u53d7\u5bb9\u4f53\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span>
                \n\u7b2c64\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u6a2a\u6d5c\uff092024\u5e7411\u67087\u65e5\u301c9\u65e5<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n
              5. \u6570\u591a \u4f38\u7d00, <\/span><\/span>\u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u65b0\u898f\u30ea\u30f3\u30ab\u30fc\u6280\u8853\u3092\u7528\u3044\u305fPSMA\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c64\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u6a2a\u6d5c\uff092024\u5e7411\u67087\u65e5\u301c9\u65e5<\/span><\/span><\/span><\/span><\/li>\n
              6. \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u8fbb \u7965\u592a\u90ce, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u7d30\u80de\u5185\u6ede\u7559\u578b\u91d1\u5c5eRI\u6a19\u8b58\u5264\u306e\u6297\u4e2d\u76ae\u816b\u6297\u4f53\u3078\u306e\u5fdc\u7528<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c64\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u6a2a\u6d5c\uff092024\u5e7411\u67087\u65e5\u301c9\u65e5<\/span><\/span><\/span><\/span><\/li>\n
              7. \u6e21\u908a \u88d5\u4e4b, \u77f3\u5742 \u512a\u8863, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>1,4-\u30b8\u30a2\u30bc\u30d1\u30f3\u9aa8\u683c\u3092\u57fa\u76e4\u3068\u3057\u305f\u30aa\u30ec\u30ad\u30b7\u30f31\u53d7\u5bb9\u4f53\u6a19\u7684PET\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c64\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u6a2a\u6d5c\uff092024\u5e7411\u67087\u65e5\u301c9\u65e5<\/span><\/span><\/span><\/span><\/li>\n
              8. \u4e2d\u91ce \u5927\u6a39, \u6e21\u908a \u88d5\u4e4b, \u9f4b\u85e4 \u6d69\u8f14, \u5c0f\u91ce \u6b63\u535a<\/span>
                \n<\/span><\/span><\/span><\/span>\u30c8\u30ea\u30a2\u30b6\u30d6\u30bf\u30b8\u30a8\u30f3\u9aa8\u683c\u3092\u7528\u3044\u305f\u30c1\u30ed\u30b7\u30f3\u7279\u7570\u7684\u4e8c\u5b98\u80fd\u6027\u30ad\u30ec\u30fc\u30c8\u8a66\u85ac\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c74\u56de \u65e5\u672c\u85ac\u5b66\u4f1a\u95a2\u897f\u652f\u90e8\u7dcf\u4f1a\u30fb\u5927\u4f1a (\u5175\u5eab) 2024\u5e7410\u67085\u65e5<\/span><\/span><\/span><\/li>\n
              9. \u9577\u8c37\u5ddd \u62d3\u771f, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                \n<\/span><\/span><\/span><\/span>\u524d\u7acb\u817a\u304c\u3093\u306e\u9ad8\u7cbe\u5ea6\u8a3a\u65ad\u3092\u76ee\u7684\u3068\u3057\u305f\u816b\u760d\u6ede\u7559\u578b\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c74\u56de \u65e5\u672c\u85ac\u5b66\u4f1a\u95a2\u897f\u652f\u90e8\u7dcf\u4f1a\u30fb\u5927\u4f1a (\u5175\u5eab) 2024\u5e7410\u67085\u65e5<\/span><\/span><\/span><\/li>\n
              10. \u67cf\u5c71 \u9678\u6597, \u6e21\u908a \u88d5\u4e4b, \u8d64\u5742 \u8cb4\u6d69, \u5c0f\u91ce \u6b63\u535a<\/span>
                \n<\/span><\/span><\/span><\/span>\u5206\u5c90\u69cb\u9020\u5c0e\u5165\u306b\u3088\u308b A\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u8fd1\u8d64\u5916\u86cd\u5149\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c74\u56de \u65e5\u672c\u85ac\u5b66\u4f1a\u95a2\u897f\u652f\u90e8\u7dcf\u4f1a\u30fb\u5927\u4f1a (\u5175\u5eab) 2024\u5e7410\u67085\u65e5<\/span><\/span><\/span><\/li>\n
              11. Shohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span>Development of novel radiotheranostic agents with albumin binder for cancer treatment<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c4\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2024\u5e749\u670825\u65e5\u301c27\u65e5<\/span><\/span><\/li>\n
              12. Takuma Hasegawa, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span>Development of tumor-residualizing radiopharmaceuticals for theranostics of prostate cancer<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c4\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2024\u5e749\u670825\u65e5\u301c27\u65e5<\/span><\/span><\/li>\n
              13. Shohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span>Development of novel pretargeting strategy for nuclear imaging and targeted radionuclide therapy of cancer<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c4\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2024\u5e749\u670825\u65e5\u301c27\u65e5<\/span><\/span><\/li>\n
              14. Nobuki Kazuta, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span>Novel PSMA-targeting radioligands with improved pharmacokinetics for diagnosis and therapy of prostate cancer<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c4\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2024\u5e749\u670825\u65e5\u301c27\u65e5<\/span><\/span><\/li>\n
              15. Kosuke Saito, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                \n<\/span><\/span><\/span>Synthesis and evaluation of c-Met-targeting radiopharmaceuticals based on peptide ligands for cancer diagnosis and therapy<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c4\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2024\u5e749\u670825\u65e5\u301c27\u65e5<\/span><\/span><\/li>\n
              16. Daiki Nakano, Hiroyuki Watanabe, Kosuke Saito, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nNovel Tyrosine-Specific Radiometal Labeling Method Using Triazabutadiene Scaffold<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span><\/span><\/li>\n
              17. Nobuki Kazuta, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nImpact of linker on pharmacokinetics of PSMA-targeting radioligands with albumin binder<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span><\/span><\/li>\n
              18. Shohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nApplication of albumin binder to pretargeting strategy for increasing tumor uptake<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span><\/span>
                \n<\/span><\/li>\n
              19. Kosuke Saito, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nFundamental study on the development of c-Met-targeting radiopharmaceuticals for the diagnosis and treatment of cancer<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span>
                \n<\/span><\/li>\n
              20. Takahiro Akasaka, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nDevelopment of Bimodal Radioactive\/Fluorescent Imaging Probe Targeting A\u03b2 Oligomers<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span>
                \n<\/span><\/li>\n
              21. Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nDevelopment of positively-charged chelating agents that control the biodistribution of radioimmunoconjugates<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span>
                \n<\/span><\/li>\n
              22. Hiroki Jinda, Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nNovel cathepsin B substrate-containing chelating agent to enhance intracellular retention of radioimmunoconjugates in tumor<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span><\/span><\/li>\n
              23. Hiroyuki Watanabe<\/span><\/span><\/span><\/span><\/span>
                \nDevelopment of Bimodal Agents for Combined Use in Auger Electron and Photodynamic Cancer Therapy<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span><\/span><\/li>\n
              24. Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nCurrent Status of Radiopharmaceutical Sciences in Japan 2024 (Plenary Lecture)<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024) (Kanazawa, Japan) September<\/span> 19-20, 2024<\/span><\/span><\/span><\/li>\n
              25. \u5c71\u53e3 \u6075\u8056, \u6570\u591a \u4f38\u7d00, \u571f\u6a4b \u660c\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                \n<\/span><\/span><\/span><\/span>\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u306b\u7740\u76ee\u3057\u305f\u524d\u7acb\u817a\u7279\u7570\u7684\u819c\u6297\u539f\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u69cb\u9020-\u89aa\u548c\u6027-\u52d5\u614b\u76f8\u95a2<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c21\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u795e\u5948\u5ddd) 2024\u5e748\u670822\u65e5, 23\u65e5<\/span><\/span><\/span><\/li>\n
              26. \u4e0b\u539f \u6ec9\u7a00, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                \n<\/span><\/span><\/span><\/span>\u653e\u5c04\u6027\u6a19\u8b58\u6297\u4f53\u306e\u4f53\u5185\u52d5\u614b\u5236\u5fa1\u3092\u76ee\u7684\u3068\u3057\u305f\u30ab\u30c1\u30aa\u30f3\u6027\u30ad\u30ec\u30fc\u30c8\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c21\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u795e\u5948\u5ddd) 2024\u5e748\u670822\u65e5, 23\u65e5<\/span><\/span><\/span><\/li>\n
              27. \u4e00\u30ce\u702c \u8cb4\u5141, \u79cb\u8449 \u5b8f\u6a39, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                \n<\/span><\/span><\/span><\/span>HER2\u6a19\u7684\u30d0\u30a4\u30d1\u30e9\u30c8\u30d4\u30c3\u30af\u6297\u4f53\u3092\u57fa\u76e4\u3068\u3057\u305f\u653e\u5c04\u6027\u6297\u4f53\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u7b2c21\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u795e\u5948\u5ddd) 2024\u5e748\u670822\u65e5, 23\u65e5<\/span><\/span><\/span><\/li>\n
              28. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                \n\u8a8d\u77e5\u75c7\u30fb\u304c\u3093\u306e\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u306b\u8cc7\u3059\u308b\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
                \n\u7b2c61\u56de\u30a2\u30a4\u30bd\u30c8\u30fc\u30d7\u30fb\u653e\u5c04\u7dda\u7814\u7a76\u767a\u8868\u4f1a (\u6771\u4eac) 2024\u5e747\u67083\u65e5\u301c\uff15\u65e5<\/span><\/span><\/li>\n
              29. Hiroyuki Watanabe, Ryotaro Onoue, Masahiro Ono<\/span><\/span><\/span><\/span><\/span>
                \nDevelopment of novel bi-modal agents for combination use of Auger electron therapy and photodynamic therapy<\/span>
                \n<\/span><\/span><\/span><\/span><\/span>Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (Toronto, Canada) June 8-11, 2024<\/span><\/span><\/span><\/li>\n
              30. \u6570\u591a \u4f38\u7d00, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                \nStructure-affinity-pharmacokinetics relationship of 111<\/sup>In-labeled prostate-specific membrane antigen-targeting radioligands<\/span><\/span><\/span>
                \n\u7b2c33\u56de\u91d1\u5c5e\u306e\u95a2\u4e0e\u3059\u308b\u751f\u4f53\u95a2\u9023\u53cd\u5fdc\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 (\u5ca1\u5c71) 2024\u5e746\u67087\u65e5, 8\u65e5<\/span><\/span><\/li>\n
              31. \u751a\u7530 \u6d38\u5e0c, \u6e21\u908a \u88d5\u4e4b, \u4e2d\u5cf6 \u4e00\u78e8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                \nApplication of microfluidic devices for automated two-step labeling of antibodies with radiometal<\/span><\/span><\/span>
                \n\u7b2c33\u56de\u91d1\u5c5e\u306e\u95a2\u4e0e\u3059\u308b\u751f\u4f53\u95a2\u9023\u53cd\u5fdc\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 (\u5ca1\u5c71) 2024\u5e746\u67087\u65e5, 8\u65e5<\/span><\/span><\/li>\n
              32. \u4e2d\u91ce \u5927\u6a39, \u6e21\u908a \u88d5\u4e4b, \u9f4b\u85e4 \u6d69\u8f14, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                \n\u30c8\u30ea\u30a2\u30b6\u30d6\u30bf\u30b8\u30a8\u30f3\u9aa8\u683c\u3092\u7528\u3044\u305f\u65b0\u898f\u30c1\u30ed\u30b7\u30f3\u7279\u7570\u7684\u91d1\u5c5eRI\u6a19\u8b58\u6cd5\u306e\u958b\u767a<\/span><\/span><\/span>
                \n\u7b2c18\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u6771\u4eac) 2024\u5e745\u670823\u65e5, 24\u65e5<\/span><\/span><\/li>\n
              33. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                \nA\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u8fd1\u8d64\u5916\u86cd\u5149\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u306e\u9ad8\u7cbe\u5ea6\u5316\u3092\u76ee\u7684\u3068\u3057\u305fBODIPY\u8a98\u5c0e\u4f53\u306e\u69cb\u9020\u6700\u9069\u5316<\/span><\/span><\/span>
                \n\u7b2c18\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u6771\u4eac) 2024\u5e745\u670823\u65e5, 24\u65e5<\/span><\/span><\/li>\n
              34. \u6e21\u908a \u88d5\u4e4b, \u9577\u5d8b \u6d69\u592a\u6717, \u8d64\u5742 \u8cb4\u6d69, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                \n\u30c8\u30ea\u30d5\u30a7\u30cb\u30eb\u30e1\u30bf\u30f3\u69cb\u9020\u3092\u57fa\u76e4\u3068\u3057\u305f\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u86cd\u5149\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
                \n\u7b2c18\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u6771\u4eac) 2024\u5e745\u670823\u65e5, 24\u65e5<\/span><\/span><\/li>\n
              35. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                \nPET\u691c\u67fb\u85ac\u306e\u88fd\u9020\u30fb\u7ba1\u7406 (PET\u7814\u4fee\u30bb\u30df\u30ca\u30fc)<\/span><\/span><\/span>
                \n\u7b2c24\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u6625\u5b63\u5927\u4f1a (\u30aa\u30f3\u30e9\u30a4\u30f3) 2024\u5e744\u670825\u65e5\u301c6\u67084\u65e5<\/span><\/span><\/li>\n
              36. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
                \nA\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u8fd1\u8d64\u5916\u86cd\u5149\u30d7\u30ed\u30fc\u30d6\u3068\u3057\u3066\u306e\u30c1\u30aa\u30d5\u30a7\u30f3\u7f6e\u63dbBODIPY\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
                \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c144\u5e74\u4f1a (\u6a2a\u6d5c) 2024\u5e743\u670828\u65e5\u301c31\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
              37. \u6e21\u908a \u88d5\u4e4b, \u5c3e\u4e0a \u907c\u592a\u90ce, \u5c0f\u91ce \u6b63\u535a
                \n\u304c\u3093\u306e\u30aa\u30fc\u30b8\u30a7\u6cbb\u7642\u304a\u3088\u3073\u5149\u7dda\u529b\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u3092\u53ef\u80fd\u306b\u3059\u308b\u4e8c\u6a5f\u80fd\u6027BODIPY\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
                \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c144\u5e74\u4f1a (\u6a2a\u6d5c) 2024\u5e743\u670828\u65e5\u301c31\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
              38. \u9f4b\u85e4 \u6d69\u8f14, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
                \n\u304c\u3093\u306e\u8a3a\u65ad\u30fb\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305fc-Met\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u8a55\u4fa1<\/span><\/span><\/span>
                \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c144\u5e74\u4f1a (\u6a2a\u6d5c) 2024\u5e743\u670828\u65e5\u301c31\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
              39. \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a
                \n\u653e\u5c04\u6027\u91d1\u5c5e\u6a19\u8b58\u6297\u4f53\u306e\u816b\u760d\u96c6\u7a4d\u6027\u306e\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u4e2d\u5206\u5b50PEG\u542b\u6709\u30ad\u30ec\u30fc\u30c8\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
                \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c144\u5e74\u4f1a (\u6a2a\u6d5c) 2024\u5e743\u670828\u65e5\u301c31\u65e5<\/span><\/span><\/span><\/span><\/span><\/li>\n
              40. \u751a\u7530 \u6d38\u5e0c, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
                \n<\/span>\u653e\u5c04\u6027\u6297\u4f53\u85ac\u5264\u306e\u816b\u760d\u6ede\u7559\u6027\u306e\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u30ab\u30c6\u30d7\u30b7\u30f3B\u8a8d\u8b58\u6027\u30ad\u30ec\u30fc\u30c8\u5264\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span>
                \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c144\u5e74\u4f1a (\u6a2a\u6d5c) 2024\u5e743\u670828\u65e5\u301c31\u65e5<\/span><\/span><\/span><\/span><\/li>\n
              41. \u6570\u591a \u4f38\u7d00, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                \n<\/span>PSMA\u6a19\u7684\u653e\u5c04\u6027\u85ac\u5264\u306e\u30a2\u30eb\u30d6\u30df\u30f3\u7d50\u5408\u6027\u3068\u816b\u760d\u96c6\u7a4d\u6027\u306e\u95a2\u9023\u306b\u95a2\u3059\u308b\u57fa\u790e\u7684\u8a55\u4fa1<\/span><\/span><\/span>
                \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c144\u5e74\u4f1a (\u6a2a\u6d5c) 2024\u5e743\u670828\u65e5\u301c31\u65e5<\/span><\/span><\/span><\/li>\n<\/ol>\n

                \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

                2023 (\u8ad6\u6587)<\/h2>\n
                  \n
                1. Onoue R, Watanabe H, Ono M.<\/span><\/span><\/span><\/span><\/span>
                  \n<\/span><\/span>Synthesis and biological evaluation of bi-modal BODIPY-conjugated Hoechst applicable for Auger-electron and photodynamic cancer therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem. Lett. <\/em>96 129534 (2023)
                  \n<\/span>DOI: 10.1016\/j.bmcl.2023.129534 <\/span><\/span><\/span><\/li>\n
                2. Akasaka T, Watanabe H, Ono M.<\/span><\/span>
                  \n<\/span><\/span>In vivo<\/em> Near-Infrared Fluorescence Imaging Selective for Soluble Amyloid \u03b2 Aggregates Using y-Shaped BODIPY Derivative<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span>J. Med. Chem.<\/em> 66(20) 14029-14046 (2023)
                  \n<\/span>DOI: 10.1021\/acs.jmedchem.3c01057<\/span><\/span><\/span><\/li>\n
                3. \u5c0f\u91ce \u6b63\u535a<\/span><\/span>
                  \n<\/span><\/span>\u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u30fb\u6838\u533b\u5b66\u5206\u91ce\u306b\u304a\u3051\u308b\u85ac\u5b66\u7cfb\u4eba\u6750\u80b2\u6210\u00a0<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span><\/span>\u653e\u5c04\u5316\u5b66<\/em> 48 41-44 (2023)<\/span><\/span><\/span><\/li>\n
                4. Nakashima K, Watanabe H, Ono M.<\/span><\/span>
                  \n<\/span><\/span>Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span>J. Med. Chem.<\/em> 66(18) 12812-12827 (2023)
                  \n<\/span>DOI: 10.1021\/acs.jmedchem.3c00472 <\/span><\/span><\/span><\/li>\n
                5. Tsuchihashi S, Nakashima K, Tarumizu Y, Ichikawa H, Jinda H, Watanabe H, Ono M.<\/span><\/span>
                  \n<\/span><\/span>Development of Novel 111<\/sup>In\/225<\/sup>Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span>J. Med. Chem.<\/em> 66(12) 8043-8053 (2023)
                  \n<\/span>DOI: 10.1021\/acs.jmedchem.3c00346 <\/span><\/span><\/span><\/li>\n
                6. Kazuta N, Watanabe H, Ono M.<\/span><\/span>
                  \n<\/span><\/span>Synthesis and Evaluation of 111<\/sup>In-labeled Tetrapeptide-based Compounds as SPECT Imaging Probes Targeting Granzyme B<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span>J. Labelled Comp. Radiopharm.<\/em> 66(10) 298-307 (2023)
                  \n<\/span>DOI: 10.1002\/jlcr.4045<\/span><\/span><\/span><\/li>\n
                7. \u5c0f\u91ce \u6b63\u535a<\/span><\/span>
                  \n<\/span><\/span>\u30a2\u30df\u30ed\u30a4\u30c9\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5264\u306e\u958b\u767a\u306b\u304a\u3051\u308b\u85ac\u5b66\u7684\u8ca2\u732e<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span><\/span>\u6838\u533b\u5b66\u6280\u8853<\/em>\u00a043 45-49 (2023)<\/span><\/span><\/span><\/li>\n
                8. Watanabe H, Ide T, Ono M.<\/span><\/span>
                  \n<\/span><\/span>Synthesis and characterization of novel radioiodinated triazole-pyrolidine derivative to detect orexin 2 receptor in the brain<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span><\/span>Chem. Pharm.\u00a0Bull.<\/em> 71(3) 234-239 (2023)
                  \n<\/span>DOI: 10.1248\/cpb.c22-00770<\/span><\/span><\/span><\/li>\n
                9. Onoue R, Watanabe H, Ono M.<\/span><\/span>
                  \n<\/span><\/span>Hoechst-tagged radioiodinated BODIPY derivative for Auger-electron cancer therapy<\/span><\/span><\/span><\/span>
                  \n<\/span><\/span><\/span><\/span>Chem. Commun.<\/em> 59 928-931 (2023)
                  \n<\/span>DOI: 10.1039\/d2cc05405a<\/span><\/span><\/span><\/li>\n<\/ol>\n

                  \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

                  2023 (\u5b66\u4f1a\u767a\u8868)<\/h2>\n
                    \n
                  1. \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u653e\u5c04\u6027\u6297\u4f53\u85ac\u5264\u306e\u816b\u760d\u6ede\u7559\u6027\u306e\u5411\u4e0a\u3092\u4f01\u56f3\u3057\u305f\u65b0\u898fPEG\u5316\u30ad\u30ec\u30fc\u30c8\u5264\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c63\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u5927\u962a\uff09 2023\u5e7411\u670816\u65e5\u301c18\u65e5<\/span><\/span><\/span><\/span><\/li>\n
                  2. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u5782\u6c34 \u52c7\u592a, \u5e02\u5ddd \u6d69\u7ae0, \u751a\u7530 \u6d38\u5e0c, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u65b0\u898f111<\/sup>In\/225<\/sup>Ac\u6a19\u8b58PSMA\u6a19\u7684\u85ac\u5264\u3092\u7528\u3044\u305f\u9ad8\u52b9\u7387\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c63\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u5927\u962a\uff09 2023\u5e7411\u670816\u65e5\u301c18\u65e5<\/span><\/span><\/span><\/span><\/li>\n
                  3. \u6e21\u908a \u88d5\u4e4b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u653e\u5c04\u7dda\u5185\u7528\u7642\u6cd5\u304a\u3088\u3073\u5149\u7dda\u529b\u5b66\u7642\u6cd5\u3092\u53ef\u80fd\u3068\u3059\u308bbi-modal\u85ac\u5264\u306e\u958b\u767a (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff09<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c63\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u5927\u962a\uff09 2023\u5e7411\u670816\u65e5\u301c18\u65e5<\/span><\/span><\/span><\/span><\/li>\n
                  4. Shohei Tsuchihashi, Kazuma Nakashima, Yuta Tarumizu, Hiroaki Ichikawa, Hiroki Jinda, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span>Development of novel radiotheranostic agent targeting prostate-specific membrane antigen for highly efficient prostate cancer therapy<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c3\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2023\u5e749\u670827\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
                  5. Takahiro Akasaka, Hiroyuki Watanabe, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span>In vivo near-infrared imaging targeting amyloid \u03b2 oligomers in model mouse of Alzheimers disease<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c3\u56de\u7814\u7a76\u4ea4\u6d41\u30b5\u30ed\u30f3<\/span><\/span><\/span>\uff08\u4eac\u90fd)\u00a0\u00a0<\/span>2023\u5e749\u670827\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
                  6. \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span>3\u5b98\u80fd\u6027\u91d1\u5c5e\u914d\u4f4d\u5b50DOTADG\u3092\u7528\u3044\u305f\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u7528\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c6\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c2\uff12<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u5343\u8449)\u00a0\u00a0<\/span>2023\u5e749\u67089\u65e5<\/span><\/span><\/li>\n
                  7. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n<\/span><\/span><\/span>\u816b\u760d\u96c6\u7a4d\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u591a\u6a5f\u80fd\u6027\u30ad\u30ec\u30fc\u30c8\u30ea\u30f3\u30ab\u30fc\u306e\u30d7\u30ec\u30bf\u30fc\u30b2\u30c6\u30a3\u30f3\u30b0\u6cd5\u3078\u306e\u5fdc\u7528<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c6\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c2\uff12<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u5343\u8449)\u00a0\u00a0<\/span>2023\u5e749\u67089\u65e5<\/span><\/span><\/li>\n
                  8. \u8d64\u5742 \u8cb4\u6d69,\u00a0<\/span><\/span>\u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                    \n<\/span><\/span><\/span><\/span>\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8fd1\u8d64\u5916\u86cd\u5149\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u6cd5\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c20\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u4eac\u90fd)\u00a02023\u5e748\u670831\u65e5, 9\u67081\u65e5<\/span><\/span><\/span><\/li>\n
                  9. \u9f4b\u85e4 \u6674\u9999, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                    \n<\/span><\/span><\/span><\/span>\u4e2d\u67a2\u30b0\u30ec\u30ea\u30f3\u53d7\u5bb9\u4f53\u306ePET\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f18<\/sup>F\u6a19\u8b58\u30b8\u30a2\u30df\u30ce\u30d4\u30ea\u30df\u30b8\u30f3\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c20\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u4eac\u90fd)\u00a02023\u5e748\u670831\u65e5, 9\u67081\u65e5<\/span><\/span><\/span><\/li>\n
                  10. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n\u30a2\u30df\u30ed\u30a4\u30c9PET\u85ac\u5264\u958b\u767a\u306e\u904e\u53bb\u30fb\u73fe\u5728\u30fb\u672a\u6765<\/span><\/span><\/span>
                    \n\u7b2c\uff14\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a \u95a2\u6771\u7532\u4fe1\u8d8a\u652f\u90e8\u4f1a (\u30aa\u30f3\u30e9\u30a4\u30f3) 2023\u5e748\u670821\u65e5<\/span><\/span><\/li>\n
                  11. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n\u91d1\u5c5e\u30ad\u30ec\u30fc\u30c8\u3092\u57fa\u76e4\u3068\u3057\u305f111<\/sup>In\/225<\/sup>Ac\u6a19\u8b58\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
                    \n\u77ed\u5bff\u547dRI\u5229\u7528\u7814\u7a76\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 (\u5927\u962a) 2023\u5e748\u67082\u65e5\u301c\uff13\u65e5<\/span><\/span><\/li>\n
                  12. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u3092\u5fd7\u5411\u3057\u305f\u6b21\u4e16\u4ee3\u653e\u5c04\u6027\u85ac\u5264\u306e\u958b\u767a\u7814\u7a76 (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff09<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u7b2c\uff13\uff15\u56de\u30d0\u30a4\u30aa\u30e1\u30c7\u30a3\u30ab\u30eb\u5206\u6790\u79d1\u5b66\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0(BMAS2023) (\u672d\u5e4c) 2023\u5e747\u670828\u65e5\u301c29\u65e5<\/span><\/span><\/li>\n
                  13. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n\u653e\u5c04\u7dda\u304c\u62d3\u304f\u65b0\u305f\u306a\u8a3a\u65ad\u30fb\u6cbb\u7642<\/span><\/span><\/span>
                    \n\u7b2c\uff13\uff11\u56de\u5343\u8449\u5927\u5b66\u85ac\u5b66\u90e8 \u85ac\u53cb\u4f1a\u751f\u6daf\u6559\u80b2\u30bb\u30df\u30ca\u30fc\u30fb\u5bae\u6728\u9ad8\u660e\u8a18\u5ff5\u8b1b\u6f14\u4f1a (\u5343\u8449) 2023\u5e747\u67088\u65e5<\/span><\/span><\/li>\n
                  14. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n\u653e\u5c04\u6027\u533b\u85ac\u54c1\u306e\u958b\u767a\u7814\u7a76\u306b\u304a\u3051\u308bRI\u5229\u7528<\/span><\/span><\/span>
                    \n\u95a2\u897f\u533b\u79d1\u5927\u5b66 RI\u8b1b\u7fd2\u4f1a \u7279\u5225\u8b1b\u6f14 (\u5927\u962a) 2023\u5e746\u670822\u65e5<\/span><\/span><\/li>\n
                  15. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                    \nA\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u3068\u3057\u3066\u306eBODIPY\u8a98\u5c0e\u4f53\u306e\u6709\u7528\u6027\u8a55\u4fa1<\/span><\/span><\/span>
                    \n\u7b2c17\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u4ed9\u53f0) 2023\u5e746\u67088\u65e5, 9\u65e5<\/span><\/span><\/li>\n
                  16. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \nPET\u691c\u67fb\u85ac\u306e\u88fd\u9020\u30fb\u7ba1\u7406 (PET\u7814\u4fee\u30bb\u30df\u30ca\u30fc)<\/span><\/span><\/span>
                    \n\u7b2c23\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u6625\u5b63\u5927\u4f1a (\u30aa\u30f3\u30e9\u30a4\u30f3) 2023\u5e744\u670826\u65e5\u301c6\u67081\u65e5<\/span><\/span><\/li>\n
                  17. \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n<\/span>\u653e\u5c04\u6027\u6297\u4f53\u85ac\u5264\u306e\u4f53\u5185\u52d5\u614b\u5236\u5fa1\u3092\u76ee\u7684\u3068\u3057\u305f\u591a\u6a5f\u80fd\u6027\u30ad\u30ec\u30fc\u30c8\u8a66\u85ac\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
                    \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c143\u5e74\u4f1a (\u672d\u5e4c) 2023\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/span><\/li>\n
                  18. \u8d64\u5742 \u8cb4\u6d69, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                    \n<\/span>BODIPY\u3092\u6bcd\u6838\u3068\u3057\u305f\u65b0\u898f\u30a2\u30df\u30ed\u30a4\u30c9\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u6a19\u7684\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
                    \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c143\u5e74\u4f1a (\u672d\u5e4c) 2023\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/span><\/li>\n
                  19. \u5c0f\u91ce \u6b63\u535a<\/span><\/span>
                    \n<\/span>\u653e\u5c04\u80fd\u52d5\u614b\u306e\u5316\u5b66\u5236\u5fa1\u3092\u57fa\u76e4\u3068\u3057\u305f\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9 (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff09<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c143\u5e74\u4f1a (\u672d\u5e4c) 2023\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/span><\/li>\n
                  20. \u6e21\u908a \u88d5\u4e4b<\/span>
                    \n<\/span><\/span>\u591a\u767a\u6027\u786c\u5316\u75c7\u306e\u75c5\u614b\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u306b\u6709\u7528\u306a\u6838\u533b\u5b66\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff09<\/span><\/span><\/span><\/span><\/span>
                    \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c143\u5e74\u4f1a (\u672d\u5e4c) 2023\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/li>\n
                  21. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
                    \n<\/span>\u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u30fb\u6838\u533b\u5b66\u5206\u91ce\u306b\u304a\u3051\u308b\u85ac\u5b66\u7cfb\u4eba\u6750\u80b2\u6210 (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0)<\/span><\/span><\/span><\/span><\/span><\/span>
                    \n\u65e5\u672c\u653e\u5c04\u5316\u5b66\u4f1a\u30fb\u6559\u80b2\u90e8\u4f1a\u3000\u7b2c2\u56de\u6559\u80b2\u30bb\u30df\u30ca\u30fc\u3000(\u7b51\u6ce2(\u30cf\u30a4\u30d6\u30ea\u30c3\u30c9))\u00a02023\u5e743\u67088\u65e5<\/span><\/span><\/span>
                    \n<\/span><\/span><\/li>\n<\/ol>\n

                    \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

                    2022 (\u8ad6\u6587)<\/h2>\n
                      \n
                    1. Nakagawa K, Watanabe H, Kaide S, Ono M.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Structure-Activity Relationships of Styrylquinoline and Styrylquinoxaline Derivatives as \u03b1-Synuclein Imaging Probes<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>ACS Med. Chem. Lett.\u00a0<\/em>13(10) 1598-1605 (2022)
                      \n<\/span>DOI: 10.1021\/acsmedchemlett.2c00279<\/span><\/span><\/span><\/span><\/li>\n
                    2. Kaide S, Watanabe H, Iikuni S, Hasegawa M, Ono M.<\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Synthesis and Evaluation of 18<\/sup>F-Labeled Chalcone Analogue for Detection of \u03b1-Synuclein Aggregates in the Brain Using the Mouse Model<\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>ACS Chem. Neurosci.<\/em> 13(20) 2982-2990 (2022)
                      \n<\/span>DOI: 10.1021\/acschemneuro.2c00473<\/span><\/span><\/span><\/span><\/li>\n
                    3. Nakashima K, Iikuni S, Watanabe H, Ono M.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Application of the Chelator-based Clickable Radiotheranostic Platform to Moderate-molecular-weight Ligands<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>ACS Med. Chem. Lett.\u00a0<\/em>13(10) 1642-1647 (2022)
                      \n<\/span>DOI: 10.1021\/acsmedchemlett.2c00320<\/span><\/span><\/span><\/span><\/li>\n
                    4. Iikuni S, Ohara T, Watanabe H, Ono M.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Structure-activity relationships and pharmacokinetics of 111<\/sup>In-labeled glucagon-like peptide-1 receptor-targeting exendin-4 derivatives conjugated with albumin binder moieties<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>Mol. Pharm.<\/em> 19(8) 2832-2839 (2022)
                      \n<\/span>DOI: 10.1021\/acs.molpharmaceut.2c00201<\/span><\/span><\/span><\/span><\/li>\n
                    5. Iikuni S, Tarumizu Y, Tsuchihashi S, Ohara T, Watanabe H, Ono M.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Synthesis and evaluation of novel 111<\/sup>In-labeled picolinic acid-based radioligands containing an albumin binder for development of radiotheranostic platform<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>Mol. Pharm.<\/em> 19(8) 2725-2736 (2022)
                      \n<\/span>DOI: 10.1021\/acs.molpharmaceut.2c00071<\/span><\/span><\/span><\/span><\/li>\n
                    6. \u8702\u9808\u8cc0 \u6681\u5b50, \u6771 \u9054\u4e5f, \u7d30\u91ce \u771e, \u5c0f\u91ce \u6b63\u535a, \u4e0a\u539f \u77e5\u4e5f, \u897f\u6751 \u4f38\u592a\u90ce, \u6751\u4e0a \u5b66, \u6e21\u9089 \u30ea\u30e9, \u6839\u5143 \u8cb4\u884c, \u9ad8\u4e95 \u5e0c\u671b, \u897f\u689d \u6b66\u660e, \u6ce2\u591a\u91ce \u6b63, \u771e\u77e2 \u5553\u53f2, \u7af9\u68ee \u82f1\u6643, \u9999\u672c \u7965\u6c70, \u4f50\u6cbb \u82f1\u90ce.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>FDA\u30ac\u30a4\u30c0\u30f3\u30b9\u300cOncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry\u300d\u306e\u65e5\u672c\u8a9e\u8a33\u304a\u3088\u3073\u88dc\u8db3\u8aac\u660e<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>\u30ec\u30ae\u30e5\u30e9\u30c8\u30ea\u30fc\u30b5\u30a4\u30a8\u30f3\u30b9\u5b66\u4f1a\u8a8c<\/em>, 12(2) 161-177 (2022)
                      \n<\/span>DOI: 10.14982\/rsmp.12.161 <\/span><\/span><\/span><\/span><\/li>\n
                    7. Akasaka T, Watanabe H, Kaide S, Iikuni S, Hasegawa M, Ono M.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Synthesis and evaluation of novel radioiodinated phenylbenzofuranone derivatives as \u03b1-synuclein imaging probes<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>Bioorg. Med. Chem. Lett.\u00a0<\/em>64 128679 (2022)
                      \n<\/span>DOI: 10.1016\/j.bmcl.2022.128679<\/span><\/span><\/span><\/span><\/li>\n
                    8. Iikuni S, Kamei I, Ohara T, Watanabe H, Ono M.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Development of an 111<\/sup>In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>Mol. Pharm.<\/em> 19(3) 1019-1027 (2022)
                      \n<\/span>DOI: 10.1021\/acs.molpharmaceut.2c00068<\/span><\/span><\/span><\/span><\/li>\n
                    9. Saito K, Watanabe H, Iikuni S, Ono M.<\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Development of novel 67\/68<\/sup>Ga-labeled pyridyl benzofuran derivatives as islet amyloid imaging probes<\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>Nucl. Med. Biol.<\/em> 106-107 72-79 (2022)
                      \n<\/span>DOI: 10.1016\/j.nucmedbio.2022.01.003<\/span><\/span><\/span><\/span><\/li>\n
                    10. Watanabe H, Maekawa R, Iikuni S, Kakae M, Matsuo N, Shirakawa H, Kaneko S, Ono M.<\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Characterization of Radioiodinated Diaryl Oxadiazole Derivatives as SPECT Probes for Detection of Myelin in Multiple Sclerosis<\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>ACS Chem. Neurosci.<\/em> 13(3) 363-369 (2022)
                      \n<\/span>DOI: 10.1021\/acschemneuro.1c00753<\/span><\/span><\/span><\/span><\/li>\n
                    11. Shimizu Y, Koyasu S, Suzukida M, Izumi K, Kidera E, Shindo T, Saga T, Ono M, Takaori-Kondo A, Nakamoto Y.<\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia\/lymphoma in vivo<\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>Ann. Nucl. Med.<\/em> 36(3) 319-326 (2022)
                      \n<\/span>DOI: 10.1007\/s12149-021-01706-4<\/span><\/span><\/span><\/span><\/span><\/li>\n
                    12. Kaide S, Watanabe H, Iikuni S, Hasegawa M, Itoh K, Ono M.<\/span><\/span><\/span>
                      \n<\/span><\/span><\/span>Chalcone Analogue as New Candidate for Selective Detection of \u03b1-Synuclein Pathology<\/span><\/span><\/span><\/span>
                      \n<\/span><\/span><\/span><\/span>ACS Chem. Neurosci.<\/em> 13(1) 16-26 (2022)
                      \n<\/span>DOI: 10.1021\/acschemneuro.1c00441 <\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n

                      2022 (\u8457\u66f8\u7b49)<\/h2>\n
                        \n
                      1. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span>
                        \n<\/span><\/span><\/span><\/span>\u653e\u5c04\u6027\u533b\u85ac\u54c1\u958b\u767a\u7814\u7a76\u3078\u306e\u62db\u5f85\u3000\u7b2c\uff14\u7ae0\u3000\u8133\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0<\/span><\/span><\/span><\/span><\/span>
                        \n\u516c\u76ca\u793e\u56e3\u6cd5\u4eba\u3000\u65e5\u672c\u30a2\u30a4\u30bd\u30c8\u30fc\u30d7\u5354\u4f1a\u7b2c\uff12\u671f\u7406\u5de5\u30fb\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u90e8\u4f1aRI\u5229\u7528\u63a8\u9032\u5c02\u9580\u59d4\u54e1\u4f1a
                        \n\u5275\u85ac\u7814\u7a76\u30ec\u30d3\u30e5\u30fc\u4f5c\u6210\u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7<\/li>\n<\/ol>\n

                        \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

                        2022 (\u5b66\u4f1a\u767a\u8868)<\/h2>\n
                          \n
                        1. Hiroyuki Watanabe, Miho Ikawa, Masahiro Ono<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n<\/span><\/span><\/span>Synthesis and evaluation of radioiodinated benzothiazole and benzoxazole derivatives for detection of myelin in multiple sclerosis<\/span><\/span><\/span><\/span><\/span><\/span>
                          \n13th Congress of the World Federation of Nuclear Medicine and Biology<\/span><\/span>\uff08Kyoto, Japan) \u00a0September 7-11, 2022<\/span><\/span><\/li>\n
                        2. \u5c3e\u4e0a \u907c\u592a\u90ce, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n<\/span><\/span><\/span>\u30aa\u30fc\u30b8\u30a7\u6cbb\u7642\u304a\u3088\u3073\u5149\u7dda\u529b\u5b66\u7642\u6cd5\u304c\u53ef\u80fd\u306aBODIPY\u7d50\u5408\u30d8\u30ad\u30b9\u30c8\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span>
                          \n\u7b2c5\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c21<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u798f\u4e95)\u00a0\u00a0<\/span>2022\u5e749\u670817\u65e5<\/span><\/span><\/li>\n
                        3. \u571f\u6a4b \u660c\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u751a\u7530 \u6d38\u5e0c, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span>
                          \n<\/span><\/span><\/span>\u76f4\u9396\u578b\u4e09\u5b98\u80fd\u6027\u30ad\u30ec\u30fc\u30c8\u69cb\u9020\u3092\u57fa\u76e4\u3068\u3057\u305f\u65b0\u898f111<\/sup>In\u6a19\u8b58PSMA\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span><\/span><\/span><\/span>
                          \n\u7b2c5\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5206\u79d1\u4f1a \u653e\u5c04\u6027\u85ac\u54c1\u79d1\u5b66\u7814\u7a76\u4f1a\/<\/span><\/span><\/span>\u7b2c21<\/span>\u56de\u653e\u5c04\u6027\u533b\u85ac\u54c1\u30fb\u753b\u50cf\u8a3a\u65ad\u85ac\u7814\u7a76\u4f1a<\/span><\/span>\uff08\u798f\u4e95)\u00a0\u00a0<\/span>2022\u5e749\u670817\u65e5<\/span><\/span><\/li>\n
                        4. \u77f3\u5742 \u512a\u8863, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span>
                          \n<\/span><\/span><\/span><\/span>\u30aa\u30ec\u30ad\u30b7\u30f31\u53d7\u5bb9\u4f53\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f18<\/sup>F\u6a19\u8b58\u30d9\u30f3\u30be\u30d5\u30e9\u30f3\u8a98\u5c0e\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n\u7b2c19\u56de\u6b21\u4e16\u4ee3\u3092\u62c5\u3046\u82e5\u624b\u306e\u305f\u3081\u306e\u30d5\u30a3\u30b8\u30ab\u30eb\u30fb\u30d5\u30a1\u30fc\u30de\u30d5\u30a9\u30fc\u30e9\u30e0 (\u6771\u4eac(\u30aa\u30f3\u30e9\u30a4\u30f3))\u00a02022\u5e749\u670812\u65e5, 13\u65e5<\/span><\/span><\/span><\/li>\n
                        5. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u30a2\u30df\u30ed\u30a4\u30c9\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5264\u306e\u958b\u767a\u306b\u304a\u3051\u308b\u85ac\u5b66\u7684\u8ca2\u732e (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n\u7b2c42\u56de\u65e5\u672c\u6838\u533b\u5b66\u6280\u8853\u5b66\u4f1a\u7dcf\u4f1a\u5b66\u8853\u5927\u4f1a\uff08\u4eac\u90fd\uff09 2022\u5e749\u67089\u65e5\u301c11\u65e5<\/span><\/span><\/span><\/span><\/li>\n
                        6. \u4e2d\u5cf6 \u4e00\u78e8, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u7528\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0ADA\u306e\u4e2d\u5206\u5b50\u30ea\u30ac\u30f3\u30c9\u306b\u5bfe\u3059\u308b\u5fdc\u7528\u6027\u306e\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n\u7b2c62\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff09 2022\u5e749\u67089\u65e5\u301c11\u65e5<\/span><\/span><\/span><\/span><\/li>\n
                        7. \u6e21\u908a \u88d5\u4e4b, \u4e95\u51fa \u5353\u5fd7, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n<\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u30aa\u30ec\u30ad\u30b7\u30f32\u53d7\u5bb9\u4f53\u3092\u6a19\u7684\u3068\u3057\u305f\u30c8\u30ea\u30a2\u30be\u30fc\u30eb-\u30d4\u30ed\u30ea\u30b8\u30f3\u985e\u7e01\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>
                          \n\u7b2c62\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff08\u4eac\u90fd\uff09 2022\u5e749\u67089\u65e5\u301c11\u65e5<\/span><\/span><\/span><\/span><\/li>\n
                        8. \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \n\u75c5\u614b\u6a5f\u80fd\u5206\u6790\u306e\u305f\u3081\u306e\u65b0\u898f\u653e\u5c04\u6027\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\u7814\u7a76 (\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0)<\/span><\/span><\/span>
                          \n\u7b2c16\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u4eac\u90fd) 2022\u5e745\u670826\u65e5, 27\u65e5<\/span><\/span><\/li>\n
                        9. \u6e21\u908a \u88d5\u4e4b, \u5cb8\u672c \u5cfb\u660e, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \n\u30a2\u30df\u30ed\u30a4\u30c9-\u03b2\u30aa\u30ea\u30b4\u30de\u30fc\u3092\u6a19\u7684\u3068\u3057\u305f\u86cd\u5149\u30d7\u30ed\u30fc\u30d6\u3068\u3057\u3066\u306e BODIPY \u8a98\u5c0e\u4f53\u306e\u8a55\u4fa1<\/span><\/span><\/span>
                          \n\u7b2c16\u56de\u65e5\u672c\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5b66\u4f1a (\u4eac\u90fd) 2022\u5e745\u670826\u65e5, 27\u65e5<\/span><\/span><\/li>\n
                        10. \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \nPET\u691c\u67fb\u85ac\u306e\u88fd\u9020\u30fb\u7ba1\u7406 (PET\u7814\u4fee\u30bb\u30df\u30ca\u30fc)<\/span><\/span><\/span>
                          \n\u7b2c22\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u6625\u5b63\u5927\u4f1a (\u30aa\u30f3\u30e9\u30a4\u30f3) 2022\u5e745\u67087\u65e5\u301c6\u67081\u65e5<\/span><\/span><\/li>\n
                        11. \u571f\u6a4b \u660c\u5e73, \u98ef\u570b \u614e\u5e73, \u4e2d\u5cf6 \u4e00\u78e8, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \n\u816b\u760d\u96c6\u7a4d\u6027\u306e\u5411\u4e0a\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898fPSMA\u6a19\u7684\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a<\/span><\/span><\/span>
                          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c142\u5e74\u4f1a (\u540d\u53e4\u5c4b(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2022\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/li>\n
                        12. \u9577\u5d8b \u6d69\u592a\u6717, \u6e21\u908a \u88d5\u4e4b, \u8c9d\u51fa \u7fd4, \u98ef\u570b \u614e\u5e73, \u9577\u8c37\u5ddd \u6210\u4eba, \u4f0a\u6771 \u606d\u5b50, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \n\u03b1\u30b7\u30cc\u30af\u30ec\u30a4\u30f3\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\u3092\u76ee\u7684\u3068\u3057\u305f\u653e\u5c04\u6027\u30d5\u30c3\u7d20\u6a19\u8b58\u30ab\u30eb\u30b3\u30f3\u985e\u7e01\u4f53\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
                          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c142\u5e74\u4f1a (\u540d\u53e4\u5c4b(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2022\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/li>\n
                        13. \u4e95\u5ddd \u5b9f\u7a42, \u6e21\u908a \u88d5\u4e4b, \u98ef\u570b \u614e\u5e73, \u62b1 \u5c06\u53f2, \u767d\u5ddd \u4e45\u5fd7, \u91d1\u5b50 \u5468\u53f8, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \n\u591a\u767a\u6027\u786c\u5316\u75c7\u306e\u8a3a\u65ad\u3092\u76ee\u7684\u3068\u3057\u305f\u30df\u30a8\u30ea\u30f3\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a\uff1a\u653e\u5c04\u6027\u30e8\u30a6\u7d20\u6a19\u8b58\u82b3\u9999\u65cf\u30d8\u30c6\u30ed\u74b0\u5316\u5408\u7269\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
                          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c142\u5e74\u4f1a (\u540d\u53e4\u5c4b(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2022\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/li>\n
                        14. \u6570\u591a \u4f38\u7d00, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
                          \n\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u7642\u6cd5\u306e\u6cbb\u7642\u52b9\u679c\u4e88\u6e2c\u306b\u8cc7\u3059\u308b\u65b0\u898f\u30b0\u30e9\u30f3\u30b6\u30a4\u30e0B\u6a19\u7684111<\/sup>In\u6a19\u8b58\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u30d7\u30ed\u30fc\u30d6\u306e\u5408\u6210\u3068\u8a55\u4fa1<\/span><\/span><\/span>
                          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c142\u5e74\u4f1a (\u540d\u53e4\u5c4b(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2022\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/li>\n
                        15. \u5c0f\u539f \u5d69\u8cb4, \u98ef\u570b \u614e\u5e73, \u6e21\u908a \u88d5\u4e4b, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span><\/span>
                          \n\u30a4\u30f3\u30b9\u30ea\u30ce\u30fc\u30de\u306e\u6838\u533b\u5b66\u8a3a\u65ad\u3092\u76ee\u7684\u3068\u3057\u305f\u65b0\u898f\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc\u7d50\u5408\u578b\u30b0\u30eb\u30ab\u30b4\u30f3\u69d8\u30da\u30d7\u30c1\u30c9-1\u53d7\u5bb9\u4f53\u6a19\u7684\u30d7\u30ed\u30fc\u30d6\u306e\u958b\u767a<\/span><\/span><\/span>
                          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c142\u5e74\u4f1a (\u540d\u53e4\u5c4b(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2022\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span><\/li>\n
                        16. \u5c3e\u4e0a \u907c\u592a\u90ce, \u6e21\u908a \u88d5\u4e4b, \u98ef\u570b \u614e\u5e73, \u5c0f\u91ce \u6b63\u535a<\/span><\/span><\/span>
                          \n\u30aa\u30fc\u30b8\u30a7\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u305f\u653e\u5c04\u6027\u30e8\u30a6\u7d20BODIPY\u7d50\u5408\u30d8\u30ad\u30b9\u30c8\u306e\u958b\u767a<\/span><\/span><\/span>
                          \n\u65e5\u672c\u85ac\u5b66\u4f1a \u7b2c142\u5e74\u4f1a (\u540d\u53e4\u5c4b(\u30aa\u30f3\u30e9\u30a4\u30f3)) 2022\u5e743\u670825\u65e5\u301c28\u65e5<\/span><\/span>
                          \n<\/span>
                          \n<\/span><\/span><\/li>\n<\/ol>\n

                          \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n

                          \n","protected":false},"excerpt":{"rendered":"

                          2026 (\u8ad6\u6587) Akiba H, Nakashima K, Ichinose T, Watanabe H, Ono M Influence of the binding valency of anti-HER2 bi […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-363","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/comments?post=363"}],"version-history":[{"count":5,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/363\/revisions"}],"predecessor-version":[{"id":3454,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/363\/revisions\/3454"}],"wp:attachment":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/media?parent=363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

                      \u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\u623b\u308b<\/a><\/p>\n